Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies

References

• Adhikari, N., Amin, S. A., Trivedi, P., Jha, T., & Ghosh, B. (2018). HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches. European Journal of Medicinal Chemistry, 157, 1127–1142. https://doi.org/10.1016/j.ejmech.2018.08.081
   PubMed Web of Science ®Google Scholar
• Bartling, B., Hofmann, H. S., Boettger, T., Hansen, G., Burdach, S., Silber, R. E., & Simm, A. (2005). Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer (Amsterdam, Netherlands), 49(2), 145–154. https://doi.org/10.1016/j.lungcan.2005.02.006
   PubMed Web of Science ®Google Scholar
• Berendsen, H. J., Van der Spoel, D., & Van Drunen, R. (1995). GROMACS: A message-passing parallel molecular dynamics implementation. Computer Physics Communications, 91(1–3), 43–56. https://doi.org/10.1016/0010-4655(95)00042-E
   Web of Science ®Google Scholar
• Bieliauskas, A. V., & Pflum, M. K. (2008). Isoform-selective histone deacetylase inhibitors. Chemical Society Reviews, 37(7), 1402–1413. https://doi.org/10.1039/b703830p
   PubMed Web of Science ®Google Scholar
• Cao, F., Zwinderman, M. R. H., & Dekker, F. J. (2018). The process and strategy for developing selective histone deacetylase 3 inhibitors. Molecules, 23(3), 551. https://doi.org/10.3390/molecules23030551
   Web of Science ®Google Scholar
• Chao, S. W., Chen, L. C., Yu, C. C., Liu, C. Y., Lin, T. E., Guh, J. H., Wang, C., Y., Chen, C. Y., Hsu, K. C., & Huang, W. J. (2018). Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities. European Journal of Medicinal Chemistry, 143, 792–805. https://doi.org/10.1016/j.ejmech.2017.11.092
   PubMed Web of Science ®Google Scholar
• Chen, J., Li, D., Li, W., Yin, J., Zhang, Y., Yuan, Z., Gao, C., Liu, F., & Jiang, Y. (2018). Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors. Bioorganic and Medicinal Chemistry, 26(14), 3958–3966.
   PubMed Web of Science ®Google Scholar
• ConfGen, Schrödinger. (2021). LLC.
   Google Scholar
• Cui, H., Hong, Q., Wei, R., Li, H., Wan, C., Chen, X., Zhao, S., Bu, H., Zhang, B., Yang, D., Lu, T., Chen, Y., & Zhu, Y. (2022). Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics. European Journal of Medicinal Chemistry, 229, 114049.
   PubMed Web of Science ®Google Scholar
• Dinakar, S., Gurubarath, M., & Dhananjayan, K. (2022). Prediction of binding affinity of 1, 2-diphenyline ketone analogues at adenosine triphosphate binding site of glycogen synthase kinase-3β: A molecular docking and dynamic simulation study. Journal of Biomolecular Structure and Dynamics, 1–16. https://doi.org/10.1080/07391102.2022.2074143
   Web of Science ®Google Scholar
• Discovery Studio. (2014). Software, version 4.1. Accelrys Software Inc.
   Google Scholar
• Desmond Molecular Dynamics System. (2018). D E Shaw research. Maestro-Desmond Interoperability Tools; Schrödinger.
   Google Scholar
• Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017). Histone deacetylase inhibitors as anticancer drugs. International Journal of Molecular Sciences, 18(7), 1414. https://doi.org/10.3390/ijms18071414
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49(21), 6177–6196.
   PubMed Web of Science ®Google Scholar
• Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 47(7), 1750–1759.
   PubMed Web of Science ®Google Scholar
• Glide (v3.4), Schrödinger. (2012). LLC.
   Google Scholar
• Guo, Z., Mohanty, U., Noehre, J., Sawyer, T. K., Sherman, W., & Krilov, G. (2010). Probing the α‐helical structural stability of stapled p53 peptides: Molecular dynamics simulations and analysis. Chemical Biology and Drug Design, 75(4), 348–359. https://doi.org/10.1111/j.1747-0285.2010.00951
   PubMed Web of Science ®Google Scholar
• Gupta, M. K., & Misra, K. (2014). Atom-based 3D-QSAR, molecular docking and molecular dynamics simulation assessment of inhibitors for thyroid hormone receptor alpha and beta. Journal of Molecular Modeling, 20(6), 2286. https://doi.org/10.1007/s00894-014-2286-5
   PubMed Web of Science ®Google Scholar
• Hou, T., Wang, J., Li, Y., & Wang, W. (2011). Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. Journal of Chemical Information and Modeling, 51(1), 69–82. https://doi.org/10.1021/ci100275a
   PubMed Web of Science ®Google Scholar
• Ibrahim, T. S., Sheha, T. A., Abo-Dya, N. E., AlAwadh, M. A., Alhakamy, N. A., Abdel-Samii, Z. K., Panda, S. S., Abuo-Rahma, G. E. A., & Mohamed, M. F. A. (2020). Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity. Bioorganic Chemistry, 99, 103797.
   PubMed Web of Science ®Google Scholar
• Ivanova, L., Tammiku-Taul, J., Garcia-Sosa, A. T., Sidorova, Y., Saarma, M., & Karelson, M. (2018). Molecular dynamics simulations of the interactions between glial cell line-derived neurotrophic factor family receptor GFRalpha1 and small-molecule ligands. ACS Omega, 3(9), 11407–11414. https://doi.org/10.1021/acsomega.8b01524
   PubMed Web of Science ®Google Scholar
• Kandasamy, S., Subramani, P., Srinivasan, K., Marshal Jayaraj, J., Prasanth, G., Muthusamy, K., Rajakannan, V., & Vilwanathan, R. (2020). Design and synthesis of imidazole based zinc binding groups as novel small molecule inhibitors targeting Histone deacetylase enzymes in lung cancer. Journal of Molecular Structure, 1214, 128177.
   Web of Science ®Google Scholar
• Khabele, D., Son, D. S., Parl, A. K., Goldberg, G. L., Augenlicht, L. H., Mariadason, J. M., & Rice, V. M. (2007). Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy. Cancer Biology & Therapy, 6(5), 795–801. https://doi.org/10.4161/cbt.6.5.4007
   PubMed Web of Science ®Google Scholar
• Kukic, P., & Nielsen, J. E. (2010). Electrostatics in proteins and protein-ligand complexes. Future Medicinal Chemistry, 2(4), 647–666. https://doi.org/10.4155/fmc.10.6
   PubMed Web of Science ®Google Scholar
• La, M. T., Jeong, B. H., & Kim, H. K. (2021). Design and Synthesis of Novel N‐(2‐aminophenyl) benzamide derivatives as histone deacetylase inhibitors and their antitumor activity study. Bulletin of the Korean Chemical Society, 42(5), 740–743.
   Web of Science ®Google Scholar
• Lee, H. Z., Kwitkowski, V. E., Del Valle, P. L., Ricci, M. S., Saber, H., Habtemariam, B. A., Bullock, j., Bloomquist, E., Li Shen, Y., Chen, X. H., Brown, J., Mehrotra, N., Dorff, S., Charlab, R., Kane, R. C., Kaminskas, E., Justice, R., Farrell, A. T., & Pazdur, R. (2015). FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clinical Cancer Research, 21(12), 2666–2670. https://doi.org/10.1158/1078-0432.CCR-14-3119
   PubMed Web of Science ®Google Scholar
• LigPrep, version 2.5, Schrodinger. (2012). LLC.
   Google Scholar
• Lill, M. (2013). Virtual screening in drug design. Methods in Molecular Biology (Clifton, N.J.), 993, 1–12. https://doi.org/10.1007/978-1-62703-342-8_1
   PubMedGoogle Scholar
• Ling, Y., Guo, J., Yang, Q., Zhu, P., Miao, J., Gao, W., Peng, Y., Yang, J., Xu, K., Xiong, B., Liu, G., Tao, J., Luo, L., Zhu, Q., & Zhang, Y. (2018). Development of novel beta-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells. European Journal of Medicinal Chemistry, 144, 398–409. https://doi.org/10.1016/j.ejmech.2017.12.061
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1–3), 3–26. https://doi.org/10.1016/S0169-409X(96)00423-1
   PubMed Web of Science ®Google Scholar
• Lyne, P. D., Lamb, M. L., & Saeh, J. C. (2006). Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. Journal of Medicinal Chemistry, 49(16), 4805–4808. https://doi.org/10.1021/jm060522a
   PubMed Web of Science ®Google Scholar
• Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007). FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. The Oncologist, 12(10), 1247–1252. https://doi.org/10.1634/theoncologist.12-10-1247
   PubMed Web of Science ®Google Scholar
• Martyna, G. J., Tobias, D. J., & Klein, M. L. (1994). Constant pressure molecular dynamics algorithms. Journal of Chemical Physics. 101(5), 4177–4189. https://doi.org/10.1063/1.467468
   Web of Science ®Google Scholar
• Mekala, J. R., Ramalingam, P. S., Mathavan, S., Yamajala, R. B., Moparthi, N. R., Kurappalli, R. K., & Manyam, R. R. (2022). Synthesis, in vitro and structural aspects of cap substituted Suberoylanilide hydroxamic acid analogs as potential inducers of apoptosis in Glioblastoma cancer cells via HDAC/microRNA regulation. Chemico-Biological Interactions, 357, 109876. https://doi.org/10.1016/j.cbi.2022.109876
   PubMed Web of Science ®Google Scholar
• Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., Jakubikova, J., Munshi, N. C., Haggarty, S. J., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2014). Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia, 28(3), 680–689. https://doi.org/10.1038/leu.2013.231
   PubMed Web of Science ®Google Scholar
• Mishra, S. S., Ranjan, S., Sharma, C. S., Singh, H. P., Kalra, S., & Kumar, N. (2021). Computational investigation of potential inhibitors of novel coronavirus 2019 through structure-based virtual screening, molecular dynamics and density functional theory studies. Journal of Biomolecular Structure & Dynamics, 39(12), 4449–4461. https://doi.org/10.1080/07391102.2020.1791957
   PubMed Web of Science ®Google Scholar
• Mulakala, C., & Viswanadhan, V. N. (2013). Could MM-GBSA be accurate enough for calculation of absolute protein/ligand binding free energies? Journal of Molecular Graphics & Modelling, 46, 41–51. https://doi.org/10.1016/j.jmgm.2013.09.005
   PubMed Web of Science ®Google Scholar
• Muller, B. M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J., Winzer, K. J., Dietel, M., Weichert, W., & Denkert, C. (2013). Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer, 13, 215. https://doi.org/10.1186/1471-2407-13-215
   PubMed Web of Science ®Google Scholar
• Neelarapu, R., Holzle, D. L., Velaparthi, S., Bai, H., Brunsteiner, M., Blond, S. Y., & Petukhov, P. A. (2011). Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes. Journal of Medicinal Chemistry, 54(13), 4350–4364. https://doi.org/10.1021/jm2001025
   PubMed Web of Science ®Google Scholar
• Negmeldin, A. T., Knoff, J. R., & Pflum, M. K. H. (2018). The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. European Journal of Medicinal Chemistry, 143, 1790–1806. https://doi.org/10.1016/j.ejmech.2017.10.076
   PubMed Web of Science ®Google Scholar
• Nguyen, H. N., & Le Thi, T. H. (2018). In silico screening, design and synthesis of novel inhibitors against histone deacetylase (HDAC). VNU Journal of Science: Medical and Pharmaceutical Sciences, 34(1), 20–28. https://doi.org/10.25073/2588-1132/vnumps.4100
   Google Scholar
• Pal, S., Kumar, V., Kundu, B., Bhattacharya, D., Preethy, N., Reddy, M. P., & Talukdar, A. (2019). Ligand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase I inhibitors. Computational and Structural Biotechnology Journal, 17, 291–310. https://doi.org/10.1016/j.csbj.2019.02.006
   PubMed Web of Science ®Google Scholar
• Patel, P., Patel, V. K., Singh, A., Jawaid, T., Kamal, M., & Rajak, H. (2019). Identification of hydroxamic acid based selective HDAC1 Inhibitors: Computer aided drug design studies. Current Computer-Aided Drug Design, 15(2), 145–166. https://doi.org/10.2174/1573409914666180502113135
   PubMed Web of Science ®Google Scholar
• Patel, P., & Rajak, H. (2018). Development of hydroxamic acid derivatives as anticancer agent with the application of 3D-QSAR, docking and molecular dynamics simulations studies. Medicinal Chemistry Research, 27(9), 2100–2115. https://doi.org/10.1007/s00044-018-2219-4
   Web of Science ®Google Scholar
• Patel, P., Singh, A., Patel, V. K., Jain, D. K., Veerasamy, R., & Rajak, H. (2016). Pharmacophore based 3D-QSAR, virtual screening and docking studies on novel series of HDAC inhibitors with thiophen linker as anticancer agents. Combinatorial Chemistry & High Throughput Screening, 19(9), 735–751. https://doi.org/10.2174/1386207319666160801154415
   PubMed Web of Science ®Google Scholar
• Peng, X., Chen, J., Li, L., Sun, Z., Liu, J., Ren, Y., Huang, J., & Chen, J. (2021). Efficient synthesis and bioevaluation of novel dual tubulin/histone deacetylase 3 inhibitors as potential anticancer agents. Journal of Medicinal Chemistry, 64(12), 8447–8473.
   PubMed Web of Science ®Google Scholar
• QikProp, Schrödinger. (2021). LLC.
   Google Scholar
• Raedler, L. A. (2016). Farydak (Panobinostat): First HDAC inhibitor approved for patients with relapsed multiple myeloma. American Health & Drug Benefits, 9(Spec Feature), 84–87.
   PubMedGoogle Scholar
• Rafi, M. O., Bhattacharje, G., Al-Khafaji, K., Taskin-Tok, T., Alfasane, M. A., Das, A. K., Parvez, M. A. K., & Rahman, M. S. (2022). Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: Analogues of lopinavir and favipiravir as potential drug candidates against COVID-19. Journal of Biomolecular Structure & Dynamics, 40(8), 3711–3730. https://doi.org/10.1080/07391102.2020.1850355
   PubMed Web of Science ®Google Scholar
• Raies, A. B., & Bajic, V. B. (2016). In silico toxicology: Computational methods for the prediction of chemical toxicity. Wiley Interdisciplinary Reviews. Computational Molecular Science, 6(2), 147–172. https://doi.org/10.1002/wcms.1240
   PubMed Web of Science ®Google Scholar
• Rajak, H., Singh, A., Raghuwanshi, K., Kumar, R., Dewangan, P. K., Veerasamy, R., Sharma, P. C., Dixit, A., & Mishra, P. (2014). A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity. Current Medicinal Chemistry, 21(23), 2642–2664. https://doi.org/10.2174/09298673113209990191
   PubMed Web of Science ®Google Scholar
• Reid, M. A., Dai, Z., & Locasale, J. W. (2017). The impact of cellular metabolism on chromatin dynamics and epigenetics. Nature Cell Biology, 19(11), 1298–1306. https://doi.org/10.1038/ncb3629
   PubMed Web of Science ®Google Scholar
• Schrödinger. (2012). Phase, version 3.4. Schrodinger, LLC.
   Google Scholar
• Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., & Sherman, W. (2010). Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. Journal of Chemical Theory and Computation, 6(5), 1509–1519. https://doi.org/10.1021/ct900587b
   PubMed Web of Science ®Google Scholar
• Singh, A., Patel, P., Patel, V. K., Jain, D. K., Kamal, M., Rajak., & H., Jageshwar. (2018). The safety, efficacy and therapeutic potential of histone deacetylase inhibitors with special reference to panobinostat in gastrointestinal tumors: A review of preclinical and clinical studies. Current Cancer Drug Targets, 18(8), 720–736. https://doi.org/10.2174/1568009617666170630124643
   PubMed Web of Science ®Google Scholar
• Singh, R., Gautam, A., Chandel, S., Sharma, V., Ghosh, A., Dey, D., Roy, S., Ravichandiran, V., & Ghosh, D. (2021). Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post‐translational modification: A multiple target approach. In Silico Pharmacology, 9, 1–16.
   PubMedGoogle Scholar
• Sirous, H., Campiani, G., Calderone, V., & Brogi, S. (2021). Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand-and structure-based virtual screening. Computers in Biology and Medicine, 137, 104808. https://doi.org/10.1016/j.compbiomed.2021.104808
   PubMed Web of Science ®Google Scholar
• Song, J., Noh, J. H., Lee, J. H., Eun, J. W., Ahn, Y. M., Kim, S. Y., Lee, S. H., Park, W. S., Yoo, N. J., Lee, J. Y., & Nam, S. W. (2005). Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 113(4), 264–268. https://doi.org/10.1111/j.1600-0463.2005.apm_04.x
   PubMed Web of Science ®Google Scholar
• Sun, H., Li, Y., Shen, M., Tian, S., Xu, L., Pan, P., Guan, Y., & Hou, T. (2014). Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. Physical Chemistry Chemical Physics: PCCP, 16(40), 22035–22045. https://doi.org/10.1039/c4cp03179b
   PubMed Web of Science ®Google Scholar
• Tripathi, M. K., Ahmad, S., Tyagi, R., Dahiya, V., & Yadav, M. K. (2022). Fundamentals of molecular modeling in drug design. In M. Rudrapal and C. Egbuna (Eds.), Computer Aided Drug Design (CADD): From ligand-based methods to structure-based approaches. Drug Discovery Updates (pp. 125–155). Elsevier. https://doi.org/10.1016/B978-0-323-90608-1.00001-0
   Google Scholar
• Ujiantari, N. S. O., Ham, S., Nagiri, C., Shihoya, W., Nureki, O., Hutchinson, D. S., & Schuster, D. (2022). Pharmacophore‐guided virtual screening to identify new β3‐adrenergic receptor agonists. Molecular informatics, 41(7), 2100223. https://doi.org/10.1002/minf.202100223
   PubMed Web of Science ®Google Scholar
• Watson, P. J., Fairall, L., Santos, G. M., & Schwabe, J. W. (2012). Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature, 481(7381), 335–340. https://doi.org/10.1038/nature10728
   PubMed Web of Science ®Google Scholar
• Watts, K. S., Dalal, P., Murphy, R. B., Sherman, W., Friesner, R. A., & Shelley, J. C. (2010). ConfGen: A conformational search method for efficient generation of bioactive conformers. Journal of Chemical Information and Modeling, 50(4), 534–546. https://doi.org/10.1021/ci100015j
   PubMed Web of Science ®Google Scholar
• Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S. (2018). The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay. Journal of Enzyme Inhibition and Medicinal Chemistry, 33(1), 525–535.
   PubMed Web of Science ®Google Scholar
• Yan, Y., An, J., Yang, Y., Wu, D., Bai, Y., Cao, W., Ma, L., Chen, J., Yu, Z., He, Y., Jin, X., Pan, Y., Ma, T., Wang, S., Hou, X., Weroha, S. J., Karnes, R. J., Zhang, J., Westerndorf, J. J., … Huang, H. (2018). Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Molecular Medicine, 10(4), e8478. https://doi.org/10.15252/emmm.201708478
   Web of Science ®Google Scholar
• Yang, J., Cheng, G., Xu, Q., Luan, S., Wang, S., Liu, D., & Zhao, L. (2018). Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif. Bioorganic and Medicinal Chemistry, 26(8), 1418–1425. https://doi.org/10.1016/j.bmc.2017.08.029
   PubMed Web of Science ®Google Scholar
• Yang, S. Y. (2010). Pharmacophore modeling and applications in drug discovery: Challenges and recent advances. Drug Discovery Today, 15(11–12), 444–450. https://doi.org/10.1016/j.drudis.2010.03.013
   PubMed Web of Science ®Google Scholar
• Yang, W., Li, L., Ji, X., Wu, X., Su, M., Sheng, L., Zang, Y., Li, J., & Liu, H. (2014). Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry, 22(21), 6146–6155. https://doi.org/10.1016/j.bmc.2014.08.030
   PubMed Web of Science ®Google Scholar
• Yang, X., Ferguson, A. T., Nass, S. J., Phillips, D. L., Butash, K. A., Wang, S. M., Herman, J. G., & Davidson, N. E. (2000). Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Research, 60(24), 6890–6894.
   PubMed Web of Science ®Google Scholar
• Zhang, X., Bao, B., Yu, X., Tong, L., Luo, Y., Huang, Q., Su, M., Sheng, L., Li, J., Zhu, H., Yang, B., Zhang, X., Chen, Y., & Lu, W. (2013). The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase. Bioorganic & Medicinal Chemistry, 21(22), 6981–6995. https://doi.org/10.1016/j.bmc.2013.09.023
   PubMed Web of Science ®Google Scholar